Quality control materials for pharmacogenomic testing in the clinic

被引:3
|
作者
Lin, Guigao [1 ,2 ]
Zhang, Kuo [1 ,2 ]
Han, Yanxi [1 ,2 ]
Li, Jinming [1 ,2 ,3 ]
机构
[1] Beijing Hosp, Natl Ctr Gerontol, Natl Ctr Clin Labs, Beijing, Peoples R China
[2] Beijing Engn Res Ctr Lab Med, Beijing, Peoples R China
[3] 1 DaHua Rd, Beijing 100730, Peoples R China
基金
中国国家自然科学基金;
关键词
next-generation sequencing; pharmaco-geno-mic testing; quality control materials; CELL LUNG-CANCER; DNA REFERENCE MATERIALS; COLORECTAL-CANCER; BREAST-CANCER; COLLABORATIVE-PROJECT; LABORATORY STANDARDS; CRISPR/CAS9; SYSTEM; MOLECULAR ANALYSIS; ROUNDS; GENERATION;
D O I
10.1515/cclm-2016-0755
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Pharmacogenomics has significantly added to our understanding of drug responses in clinical pharmacology, changing the paradigm of treatment decisions. Interrogations of both inherited and somatic variations for therapeutic purposes are increasingly being adopted in clinics, where quality control (QC) materials are required. However, for many pharmacogenomic tests, the acquisition of well-characterized QC materials is often difficult or impossible. In this review, several sources of appropriate QC materials for therapy-associated genetic testing are discussed. Among them, the novel methods for producing renewable controls that resemble patient samples are highlighted. Owing to technological complexity, more efforts are needed to develop proper controls for next-generation sequencing-based assay.
引用
收藏
页码:926 / 933
页数:8
相关论文
共 50 条
  • [41] CONTROL ADVANCES FOR MATERIALS TESTING
    不详
    PROCESSING, 1979, 25 (07): : 57 - 57
  • [42] Adoption of Pharmacogenomic Testing: A Marketing Perspective
    Koufaki, Margarita-Ioanna
    Karamperis, Kariofyllis
    Vitsa, Polixeni
    Vasileiou, Konstantinos
    Patrinos, George P.
    Mitropoulou, Christina
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [43] Erlotinib and patterns of pharmacogenomic (PGx) testing
    De Souza, Jonas A.
    Gleason, Patrick P.
    Starner, Catherine I.
    Qiu, Yang P.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (34)
  • [44] Pharmacogenomic Testing and Personalized Treatment of Depression
    Perlis, Roy H.
    CLINICAL CHEMISTRY, 2014, 60 (01) : 53 - 59
  • [45] Misleading Guidance From Pharmacogenomic Testing
    Rahman, Tahir
    Ash, David M.
    Lauriello, John
    Rawlani, Roshni
    AMERICAN JOURNAL OF PSYCHIATRY, 2017, 174 (10): : 922 - 924
  • [46] Pharmacogenomic Testing to Select Antiplatelet Therapy
    Price, Matthew J.
    Angiolillo, Dominick J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (17) : 1878 - 1881
  • [47] Insurance coverage for pharmacogenomic testing in the USA
    Williams, Marc S.
    PERSONALIZED MEDICINE, 2007, 4 (04) : 479 - 487
  • [48] DIFFERENT STAKEHOLDER PERSPECTIVES ON PHARMACOGENOMIC TESTING
    Patel, H.
    Ursan, I
    Zueger, P.
    Pickard, A. S.
    VALUE IN HEALTH, 2013, 16 (03) : A244 - A244
  • [49] Quality control for the in-clinic veterinary laboratory and pre-analytic considerations for specialized diagnostic testing
    Camus, Melinda S.
    VETERINARY JOURNAL, 2016, 215 : 3 - 9
  • [50] Trends and impacts, interesting diagnoses, quality control and new testing in the Virginia Tech Plant Disease Clinic
    Bush, E. A.
    Hansen, M. A.
    PHYTOPATHOLOGY, 2020, 110 (07) : 25 - 25